The Wall Street Journal reports that pharmaceutical giant, Johnson & Johnson, may pay up to $2.2 billion to settle claims for its Risperdal marketing practices, and the settlement may include a criminal fine of approximately $400 million. The settlement would allow Johnson & Johnson to continue to sell its products to government programs. The final sum of the settlement depends on the states that choose to join the settlement. The claims against Johnson & Johnson stem from its off-label marketing of the anti-psychotic drug. The deal also settles claims against J&J for other drugs, including Invega, a drug approved for treating mental illness, and its heart failure drug, Natrecor. The settlement also closes an investigation into kickbacks J&J allegedly made to nursing home [pharmacy operator, Omnicare.
For more information, please see: